Generation of B-cell-based cellular vaccine for cancer in murine models

David Hou, Joshua L. Katz, Catalina Lee-Chang*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


A B-cell-based cellular vaccine (BVax), produced from 4-1BBL+ B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for BVax production involving glioma cell implantation, tissue harvesting, 4-1BBL+ B cell isolation, and activation. We also describe assessing BVax phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).1

Original languageEnglish (US)
Article number102219
JournalSTAR Protocols
Issue number2
StatePublished - Jun 16 2023


  • Cancer
  • Immunology

ASJC Scopus subject areas

  • General Biochemistry, Genetics and Molecular Biology
  • General Immunology and Microbiology
  • General Neuroscience


Dive into the research topics of 'Generation of B-cell-based cellular vaccine for cancer in murine models'. Together they form a unique fingerprint.

Cite this